{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T07:47:16Z","timestamp":1788680836026,"version":"build-2803163510"},"reference-count":32,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","valueinhealthjournal.com","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.jval.2021.07.008","type":"journal-article","created":{"date-parts":[[2021,8,28]],"date-time":"2021-08-28T22:46:57Z","timestamp":1630190817000},"page":"47-58","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["A Systematic Review of Health Technology Assessments of Chimeric Antigen Receptor T-Cell Therapies in Young Compared With Older Patients"],"prefix":"10.1016","volume":"25","author":[{"given":"Amy","family":"Gye","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Goodall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"De Abreu Lourenco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.jval.2021.07.008_bib1","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.jval.2019.03.014","article-title":"Estimating the clinical pipeline of cell and gene therapies and their potential economic impact on the US healthcare system","volume":"22","author":"Quinn","year":"2019","journal-title":"Value Health"},{"issue":"2","key":"10.1016\/j.jval.2021.07.008_bib2","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.hoc.2017.11.007","article-title":"Gene therapy and genome editing [published correction appears in Hematol Oncol Clin North Am. 2018;32(3):xiii]","volume":"32","author":"Boulad","year":"2018","journal-title":"Hematol Oncol Clin North Am"},{"issue":"11","key":"10.1016\/j.jval.2021.07.008_bib3","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1002\/emmm.201202287","article-title":"Gene therapy on the move","volume":"5","author":"Kaufmann","year":"2013","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.jval.2021.07.008_bib6","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.79.3570","article-title":"What can cost-effectiveness analysis tell us about chimeric antigen receptor T-cell therapy for relapsed acute lymphoblastic leukemia? [published online ahead of print, 2018]","author":"Flowers","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.jval.2021.07.008_bib7","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.hlpt.2019.05.009","article-title":"Modelling uncertainty in survival and cost-effectiveness is vital in the era of gene therapies: the case of axicabtagene ciloleucel","volume":"8","author":"Raymakers","year":"2019","journal-title":"Health Policy Technol"},{"issue":"7","key":"10.1016\/j.jval.2021.07.008_bib8","first-page":"793","article-title":"Value-based pricing for emerging gene therapies: the economic case for a higher cost-effectiveness threshold","volume":"25","author":"Garrison","year":"2019","journal-title":"J\u00a0Manag Care Spec Pharm"},{"issue":"6","key":"10.1016\/j.jval.2021.07.008_bib9","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.jval.2019.03.012","article-title":"Analytic considerations in applying a general economic evaluation reference case to gene therapy","volume":"22","author":"Drummond","year":"2019","journal-title":"Value Health"},{"issue":"7","key":"10.1016\/j.jval.2021.07.008_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta21070","article-title":"The assessment and appraisal of regenerative medicines and cell therapy products: an exploration of methods for review, economic evaluation and appraisal","volume":"21","author":"Hettle","year":"2017","journal-title":"Health Technol Assess"},{"key":"10.1016\/j.jval.2021.07.008_bib12","author":"Chapman"},{"key":"10.1016\/j.jval.2021.07.008_bib14","author":"Cowling"},{"issue":"4","key":"10.1016\/j.jval.2021.07.008_bib16","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.jval.2016.12.003","article-title":"Policies for use of real-world data in health technology assessment (HTA): a comparative study of six HTA agencies","volume":"20","author":"Makady","year":"2017","journal-title":"Value Health"},{"issue":"1","key":"10.1016\/j.jval.2021.07.008_bib17","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s41669-018-0088-x","article-title":"International HTA experience with targeted therapy approvals for lung cancer","volume":"3","author":"Maraiki","year":"2019","journal-title":"Pharmacoecon Open"},{"issue":"5","key":"10.1016\/j.jval.2021.07.008_bib18","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.ijsu.2010.02.007","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement [published correction appears in Int J Surg. 2010;8(8):658]","volume":"8","author":"Moher","year":"2010","journal-title":"Int J Surg"},{"issue":"5","key":"10.1016\/j.jval.2021.07.008_bib19","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"16","key":"10.1016\/j.jval.2021.07.008_bib20","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia [published correction appears in N Engl J Med. 2016;374(10):998]","volume":"371","author":"Maude","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"36","key":"10.1016\/j.jval.2021.07.008_bib21","doi-asserted-by":"crossref","first-page":"4381","DOI":"10.1200\/JCO.2016.67.3301","article-title":"Phase I\/Phase II study of blinatumomab in pediatric patients with relapsed\/refractory acute lymphoblastic leukemia","volume":"34","author":"von Stackelberg","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"12","key":"10.1016\/j.jval.2021.07.008_bib22","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1200\/JCO.2005.03.8554","article-title":"Phase II study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia","volume":"24","author":"Jeha","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"issue":"23","key":"10.1016\/j.jval.2021.07.008_bib23","doi-asserted-by":"crossref","first-page":"6043","DOI":"10.1182\/blood-2011-08-374710","article-title":"Phase 2 trial of clofarabine in combination with etoposide and cyclophosphamide in pediatric patients with refractory or relapsed acute lymphoblastic leukemia","volume":"118","author":"Hijiya","year":"2011","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jval.2021.07.008_bib24","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"26","key":"10.1016\/j.jval.2021.07.008_bib25","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","article-title":"Chimeric antigen receptor T cells in refractory B-cell lymphomas","volume":"377","author":"Schuster","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"16","key":"10.1016\/j.jval.2021.07.008_bib26","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","article-title":"Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study [published correction appears in Blood. 2018;131(5):587-588]","volume":"130","author":"Crump","year":"2017","journal-title":"Blood"},{"issue":"27","key":"10.1016\/j.jval.2021.07.008_bib27","doi-asserted-by":"crossref","first-page":"4184","DOI":"10.1200\/JCO.2010.28.1618","article-title":"Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era [published correction appears in J Clin Oncol. 2012;30(15):1896]","volume":"28","author":"Gisselbrecht","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.jval.2021.07.008_bib28","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of\u00a0axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a\u00a0single-arm, multicentre, phase 1-2 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.jval.2021.07.008_bib30","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1002\/pbc.25451","article-title":"Using nonrandomized studies to inform complex clinical decisions: the thorny issue of cranial radiation therapy for T-cell acute lymphoblastic leukemia","volume":"62","author":"Kelly","year":"2015","journal-title":"Pediatr Blood Cancer"},{"issue":"7","key":"10.1016\/j.jval.2021.07.008_bib31","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1080\/10428194.2017.1390230","article-title":"Exploring the potential cost-effectiveness of precision medicine treatment strategies for\u00a0diffuse large B-cell lymphoma","volume":"59","author":"Chen","year":"2018","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.jval.2021.07.008_bib35","author":"Latimer"},{"key":"10.1016\/j.jval.2021.07.008_bib37","author":"Crabb"},{"issue":"5","key":"10.1016\/j.jval.2021.07.008_bib38","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1001\/jamapediatrics.2018.0049","article-title":"Considerations for cost-effectiveness analysis of curative pediatric therapies","volume":"172","author":"Whittington","year":"2018","journal-title":"JAMA Pediatr"},{"issue":"4","key":"10.1016\/j.jval.2021.07.008_bib39","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1200\/JCO.19.01558","article-title":"Valuing chimeric antigen receptor T-cell therapy: current evidence, uncertainties, and payment implications","volume":"38","author":"Whittington","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"10.1016\/j.jval.2021.07.008_bib40","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1111\/bcp.14275","article-title":"A\u00a0systematic review of economic evaluations of advanced therapy medicinal products","volume":"87","author":"Lloyd-Williams","year":"2021","journal-title":"Br J Clin Pharmacol"},{"issue":"22","key":"10.1016\/j.jval.2021.07.008_bib41","doi-asserted-by":"crossref","first-page":"5858","DOI":"10.1182\/bloodadvances.2020003391","article-title":"C(h)AR-ting a new course in incurable lymphomas: CAR T cells for mantle cell and follicular lymphomas","volume":"4","author":"Jacobson","year":"2020","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.jval.2021.07.008_bib56","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s12874-019-0666-3","article-title":"A\u00a0review of spline function procedures in R","volume":"19","author":"Perperoglou","year":"2019","journal-title":"BMC Med Res Methodol"}],"container-title":["Value in Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301521016508?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301521016508?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,17]],"date-time":"2024-08-17T10:20:23Z","timestamp":1723890023000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098301521016508"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["S1098301521016508"],"URL":"https:\/\/doi.org\/10.1016\/j.jval.2021.07.008","relation":{},"ISSN":["1098-3015"],"issn-type":[{"value":"1098-3015","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Systematic Review of Health Technology Assessments of Chimeric Antigen Receptor T-Cell Therapies in Young Compared With Older Patients","name":"articletitle","label":"Article Title"},{"value":"Value in Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jval.2021.07.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 ISPOR-The professional society for health economics and outcomes research. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}